ARTICLE | Clinical News
Elsiglutide: Phase IIb data
May 9, 2016 7:00 AM UTC
Top-line data from a double-blind, European Phase IIb trial in 497 colorectal cancer patients receiving 5-fluorouracil (5-FU) showed that once-daily subcutaneous elsiglutide missed the primary endpoin...